Online inquiry

IVTScrip™ mRNA-Anti-IL6, CLLB8(Cap 1, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ5970MR)

This product GTTS-WQ5970MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets IL6 gene. The antibody can be applied in Renal cell carcinoma (RCC) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Chimeric
RefSeq NM_000600.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3569
UniProt ID P05231
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL6, CLLB8(Cap 1, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ5970MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ8338MR IVTScrip™ mRNA-Anti-TFRC, HN-66000(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA HN-66000
GTTS-WQ9290MR IVTScrip™ mRNA-Anti-TACSTD2, IMMU-132(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA IMMU-132
GTTS-WQ15804MR IVTScrip™ mRNA-Anti-CD3E&IL3RA, XmAb14045(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA XmAb14045
GTTS-WQ8735MR IVTScrip™ mRNA-Anti-CCR5, HuPRO-140(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA HuPRO-140
GTTS-WQ15263MR IVTScrip™ mRNA-Anti-phosphatidylserine, Tarvacin ch3G4(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA Tarvacin ch3G4
GTTS-WQ10809MR IVTScrip™ mRNA-Anti-G, M777-16-3(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA M777-16-3
GTTS-WQ2911MR IVTScrip™ mRNA-Anti-IL17RA, AMG827(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA AMG827
GTTS-WQ2876MR IVTScrip™ mRNA-Anti-CCR4, AMG-761(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA AMG-761
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW